nejm glp 1 publishes Phase 3 trial results for orforglipron, an oral GLP-1 obesity medication. | Scott Isaacs, MD, FACP, FACE posted on the topic Fair Allocation of GLP-1 and

Available from: Hampl SE, Hassink SG, Skinner AC, Armstrong SC, Barlow SE, Bolling CF et al

PMID: 64 ZhangPZhouCRenXJingQGaoYYangCet al

The researchers compared the one-year risk of heart failure hospitalization or death in new users of each GLP-1 drug to the risk of those outcomes in a placebo group of patients taking sitagliptin, a diabetes drug known to have no impact on HFpEF

This solution is intended only as a diluent or solvent for the preparation of medications for intravenous, intramuscular, or subcutaneous injection , according to the specific instructions provided by the drug manufacturer

Lack of association between fingernail selenium and thyroid cancer risk: A case-control study in French Polynesia

Aw, Redox biology of the intestine